Raw research findings for this medication. Mostly single studies, not curated or confirmed robust.
Nilotinib is a targeted cancer medicine, a tyrosine kinase inhibitor: it blocks BCR-ABL, the abnormal fusion protein that drives chronic myeloid leukaemia (CML). It is used for CML that carries the Philadelphia chromosome, as first treatment or when imatinib has not worked. It is sold as Tasigna.
Nilotinib blocks the liver enzyme UGT1A1, which clears bilirubin, so bilirubin often rises during treatment. People with the low-activity UGT1A1 version behind Gilbert's syndrome (two copies of *28) are more likely to develop high bilirubin, which the US FDA lists as affecting safety; there is no CPIC or DPWG guideline. Whether the medicine works depends on the BCR-ABL fusion and mutations in the leukaemia cells, which arise in the cancer and are not part of the DNA a person was born with.
Clinical guidelines that name a gene for Nilotinib. They sort people into groups by the gene copies they carry.
US FDA: UGT1A1. Poor Metabolizer. Data that Indicate a Potential Impact on Safety or Response.
Every published finding on gene variants and Nilotinib. Upload your DNA file to see which of these rows apply to you.
PharmGKB weighs all studies of a variant and rates how strong the evidence is, from 1A (strongest) to 4.
UGT1A1 UGT1A1*1, UGT1A1*6, UGT1A1*27, UGT1A1*28: Level 3. Toxicity: Hyperbilirubinemia. 2.
ABCG2 rs2231137: Level 3. Other. 1.
ABCG2 rs41282401: Level 3. Other. 1.
ABCG2 rs1061018: Level 3. Other. 1.
Studies of how well it worked in people carrying a variant.
Studies of how much of the drug people needed or tolerated.
Study findings and evidence levels: PharmGKB (CC BY-SA 4.0). Guidelines: CPIC and DPWG, as bundled in PharmCAT. Most studies were done mainly in people of European ancestry.
More drugs from the same category
Apatinib (Tyrosine Kinase Inhibitors)
Gilotrif (Tyrosine Kinase Inhibitors)
Gleevec (Tyrosine Kinase Inhibitors)
Not a prescribing recommendation. This page is educational information about pharmacogenomic research and clinical guidelines - it is not medical or dosing advice, and not a prediction of how any medication will work for you. Never start, stop, or change a medication or dose based on it; talk to your doctor or pharmacist, who can order clinical-grade testing if appropriate.
Content updated September 2026.
ReadYourDNA provides educational interpretation of DNA data you already have. It is not diagnostic, not a substitute for professional medical advice, diagnosis, or treatment, and is not intended to diagnose, treat, cure, or prevent any disease. Talk to a clinician before acting on any result.
Raw DNA Data Reports for 23andMe & AncestryDNA · About ReadYourDNA · FAQ · Methodology & Science · Pricing · Support and complaints · Legal & Contact · Health Traits · Pharmacogenomics · Carrier Status · Variant Explorer · The Human Karyotype · Privacy Policy · Terms of Service · Accessibility · Consumer Health Data Privacy · Your Privacy Choices · Editorial Standards · Your Data, Checkable · Sample Report · ReadYourDNA and Promethease compared · What is inside a 23andMe raw data file · What is inside an AncestryDNA raw data file · What a chatbot can and cannot do with your raw DNA file · Where a raw DNA file can still be uploaded in 2026
Written, maintained and operated by Martin Pechhacker, sole proprietor, Vienna, Austria. Trade register GISA 40064420. support@readyourdna.com